CAMBRIDGE, Mass., June 20, 2025 -- Wave Life Sciences Ltd. (Nasdaq: WVE) has announced the presentation of preclinical data supporting their investigational drug WVE-007 at the American Diabetes Association's 85th Annual Scientific Sessions in Chicago. WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, targeting obesity with evidence from human genetics. The preclinical data demonstrated the drug's capacity to reduce INHBE mRNA and Activin E protein, facilitate weight loss primarily through fat mass reduction, and diminish pro-inflammatory macrophage recruitment in a diet-induced obese mouse model. These findings were highlighted in an oral presentation at the event, which takes place from June 20 to 23, 2025. Wave Life Sciences is currently evaluating WVE-007 in their ongoing INLIGHT clinical trial, with the first clinical data expected in the latter half of this year.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。